ABP 938

DRUG2 trials

Sponsors

Amgen

Conditions

Chorioretinal Vascular DiseaseNeovascular (Wet) Age-related Macular Degeneration (AMD)

Phase 3

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

CompletedNCT04270747

AmgenNeovascular (Wet) Age-related Macular Degeneration (AMD)

Start: 2020-06-22End: 2023-01-30Updated: 2025-09-10

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

CompletedNCT05704725

AmgenChorioretinal Vascular Disease

Start: 2023-01-23End: 2023-03-24Updated: 2025-02-14

Related Papers

Pharmacokinetic, Safety, and Immunogenicity Similarity of High‐ and Low‐Concentration Formulations of Adalimumab Biosimilar <scp>ABP</scp> 501, Adalimumab‐Atto

Pharmacology Research & Perspectives2026-03-19